{"id":"autologous-fecal-microbiota-transplantation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Abdominal pain"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This procedure aims to restore a healthy balance of gut bacteria, which can be disrupted by various factors such as antibiotics, diet, or disease. By transplanting the patient's own fecal microbiota, the goal is to promote a diverse and resilient gut microbiome that can help maintain overall health and prevent disease.","oneSentence":"Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:49.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Clostridioides difficile infection"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05998213","phase":"PHASE2","title":"Transfer of Feces in Ulcerative Colitis 2","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-06-12","conditions":"Ulcerative Colitis, Ulcerative Colitis Flare, Ulcerative Colitis Acute","enrollment":85},{"nctId":"NCT04745221","phase":"NA","title":"Efficacy and Safety of Auto-FMT in Preventing aGVHD","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-03-01","conditions":"Graft Versus Host Disease, Acute","enrollment":100},{"nctId":"NCT02269150","phase":"PHASE2","title":"Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10","conditions":"Allogeneic Hematopoietic Stem Cell","enrollment":59},{"nctId":"NCT05776914","phase":"PHASE2","title":"Fecal Microbiota Transplantation for IBS","status":"RECRUITING","sponsor":"Madhusudan (Madhu) Grover, MBBS","startDate":"2024-04-15","conditions":"Irritable Bowel Syndrome, Diarrhea","enrollment":43},{"nctId":"NCT07083882","phase":"PHASE2","title":"Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09","conditions":"Type 1 Diabetes Mellitis, Type 1 Diabetes (T1D), Fecal Microbiota Therapy (FMT)","enrollment":110},{"nctId":"NCT05204641","phase":"PHASE2","title":"Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":59},{"nctId":"NCT02970877","phase":"PHASE2","title":"Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients","status":"COMPLETED","sponsor":"Johane Allard","startDate":"2017-03-01","conditions":"Obesity, Morbid, Insulin Resistance","enrollment":29},{"nctId":"NCT06268990","phase":"NA","title":"FMT in Obesity: RYGB vs. LEAN vs. Autologous FMT","status":"RECRUITING","sponsor":"Wiebke Kristin Fenske","startDate":"2023-01-01","conditions":"Morbid Obesity, Metabolic Syndrome, Diabetes","enrollment":30},{"nctId":"NCT05803980","phase":"NA","title":"Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome Without Constipation","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-12-23","conditions":"Irritable Bowel Syndrome","enrollment":35},{"nctId":"NCT05803993","phase":"NA","title":"Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-12-23","conditions":"Irritable Bowel Syndrome","enrollment":35},{"nctId":"NCT06782880","phase":"NA","title":"Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-05-01","conditions":"Fecal Microbiota Transplantation, Orthotopic Liver Transplantation, Multi-drug Resistant Bacteria","enrollment":144},{"nctId":"NCT06609980","phase":"PHASE1","title":"Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-08-01","conditions":"Antibiotic Treatment","enrollment":40},{"nctId":"NCT04188743","phase":"PHASE2, PHASE3","title":"Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2019-12-18","conditions":"Resistance Bacterial","enrollment":150},{"nctId":"NCT06451588","phase":"PHASE2","title":"Fecal Microbiota Transplantation in Axial Spondyloarthritis","status":"RECRUITING","sponsor":"University Hospital of North Norway","startDate":"2024-06-01","conditions":"Axial Spondyloarthritis, Ankylosing Spondylitis, Dysbiosis","enrollment":99},{"nctId":"NCT04691544","phase":"PHASE3","title":"Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital of North Norway","startDate":"2021-05-05","conditions":"Irritable Bowel Syndrome","enrollment":450},{"nctId":"NCT03691987","phase":"PHASE2","title":"The Comeback Study","status":"COMPLETED","sponsor":"University Hospital of North Norway","startDate":"2019-02-15","conditions":"Chronic Fatigue Syndrome, Myalgic Encephalomyelitis","enrollment":80},{"nctId":"NCT04203017","phase":"PHASE1","title":"Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2019-06-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT05755308","phase":"NA","title":"Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":114},{"nctId":"NCT04577729","phase":"NA","title":"The IRMI-FMT Trial","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2021-05-21","conditions":"Fecal Microbiota Transplantation, Malignant Melanoma Stage III, Malignant Melanoma Stage IV","enrollment":5},{"nctId":"NCT03808389","phase":"NA","title":"Fecal Microbiota Transplantation for Parkinson's Disease","status":"COMPLETED","sponsor":"University Ghent","startDate":"2020-12-01","conditions":"Parkinson Disease","enrollment":49},{"nctId":"NCT03273855","phase":"NA","title":"Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity","status":"UNKNOWN","sponsor":"University Hospital of North Norway","startDate":"2019-05-13","conditions":"Obesity, Morbid","enrollment":60},{"nctId":"NCT03279224","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder","status":"UNKNOWN","sponsor":"Valerie Taylor","startDate":"2018-01-01","conditions":"Bipolar Depression","enrollment":35},{"nctId":"NCT05323162","phase":"NA","title":"Encapsulated Faecal Microbiota Transplantation to Preserve Residual Beta Cell Function in Type 1 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Nordin Hanssen","startDate":"2022-04","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT03074227","phase":"NA","title":"The FAIS-Trial: Faecal Microbiota Transplantation (FMT) in Adolescents With Refractory Irritable Bowel Syndrome (IBS)","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2017-11-23","conditions":"Irritable Bowel Syndrome","enrollment":30},{"nctId":"NCT03061097","phase":"PHASE1","title":"Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization","status":"COMPLETED","sponsor":"Microbiome Health Research Institute","startDate":"2017-07-10","conditions":"Antibiotic Resistant Strain","enrollment":7},{"nctId":"NCT02928523","phase":"PHASE1, PHASE2","title":"PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients","status":"COMPLETED","sponsor":"MaaT Pharma","startDate":"2016-06","conditions":"Leukemia, Myeloid, Acute","enrollment":20},{"nctId":"NCT04465032","phase":"PHASE4","title":"The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2019-12-10","conditions":"NAFLD","enrollment":20},{"nctId":"NCT03492502","phase":"NA","title":"Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2019-08-01","conditions":"Fecal Microbiota Transplantation in Graft vs. Host Disease","enrollment":""},{"nctId":"NCT02092402","phase":"NA","title":"Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Örebro University, Sweden","startDate":"2013-09","conditions":"Irritable Bowel Syndrome (IBS)","enrollment":17},{"nctId":"NCT03561532","phase":"NA","title":"Fecal Transplantation in Ulcerative Colitis","status":"UNKNOWN","sponsor":"Joint Authority for Päijät-Häme Social and Health Care","startDate":"2016-10-01","conditions":"Ulcerative Colitis","enrollment":48},{"nctId":"NCT04011943","phase":"NA","title":"Fecal Microbiota Transplantation for Health Improvement (TFM3)","status":"UNKNOWN","sponsor":"Federal Research and Clinical Center of Physical-Chemical Medicine","startDate":"2018-05-21","conditions":"Ulcerative Colitis, Irritable Bowel Syndrome, Crohn Disease","enrollment":50},{"nctId":"NCT03726645","phase":"EARLY_PHASE1","title":"The Effect of Fecal Microbiota Transplantation in Ankylosing Spondylitis (AS) Patients.","status":"UNKNOWN","sponsor":"Hospital District of Helsinki and Uusimaa","startDate":"2018-10-24","conditions":"Ankylosing Spondylitis","enrollment":20},{"nctId":"NCT03944096","phase":"PHASE2","title":"Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Rheumatoid Arthritis Refractory to Methotrexate","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-04-30","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT02496390","phase":"PHASE1, PHASE2","title":"Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-06","conditions":"Diabetes Mellitus, Non-alcoholic Fatty Liver Disease","enrollment":21},{"nctId":"NCT03561519","phase":"NA","title":"FMT in the Treatment of IBS","status":"COMPLETED","sponsor":"Joint Authority for Päijät-Häme Social and Health Care","startDate":"2015-08-27","conditions":"Irritable Bowel Syndrome","enrollment":52},{"nctId":"NCT03110289","phase":"NA","title":"Restoration of the Microbiome Through Superdonor Selection","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-04-30","conditions":"Ulcerative Colitis","enrollment":108},{"nctId":"NCT03218579","phase":"NA","title":"Endoscopic Assessment and Prediction of Microbiome-modifying Interventions","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2013-02-01","conditions":"Gut Microbiome, Antibiotic Side Effect","enrollment":45},{"nctId":"NCT02423421","phase":"PHASE2","title":"Faecal Microbiota Transplantation in Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"University College Cork","startDate":"2015-03","conditions":"Irritable Bowel Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MaaT011"],"phase":"phase_2","status":"active","brandName":"Autologous Fecal Microbiota Transplantation","genericName":"Autologous Fecal Microbiota Transplantation","companyName":"MaaT Pharma","companyId":"maat-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome. Used for Moderate to severe Clostridioides difficile infection, Ulcerative colitis.","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}